Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 461Melanoma 300Squamous Cell Carcinoma of Head and Neck 234Parkinson Disease 4, Autosomal Dominant Lewy Body 189Neoplasms 185Breast Neoplasms 162Triple Negative Breast Neoplasms 161Neoplasm Metastasis 156Lung Neoplasms 146Colorectal Neoplasms 142Carcinoma, Renal Cell 132Head and Neck Neoplasms 123Stomach Neoplasms 104Ovarian Neoplasms 100Carcinoma, Transitional Cell 91Urinary Bladder Neoplasms 81Pancreatic Neoplasms 81Carcinoma, Hepatocellular 74Endometrial Neoplasms 72Uterine Cervical Neoplasms 63Esophageal Neoplasms 57Recurrence 52Prostatic Neoplasms 49Sarcoma 43Carcinoma 42Glioblastoma 40Carcinoma, Squamous Cell 39Small Cell Lung Carcinoma 38Hodgkin Disease 36Cholangiocarcinoma 35

Interventions

pembrolizumab 2atezolizumab 2trastuzumab deruxtecan 1toripalimab 1pertuzumab 1fludarabine 1durvalumab 1cabazitaxel 1XRP6258 1Trastuzumab 1S-Adenosylmethionine 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cyclophosphamide 1Cetuximab 1Carboplatin 1Capecitabine 1Bronchoscopes 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Solid Cancer × pembrolizumab × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated
7 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡